key: cord-0746395-cydf45t1
authors: Levine, Robert S.; Johnson, Heather M.; Maki, Dennis G.; Hennekens, Charles H.
title: Racial Inequalities in Mortality from Coronavirus: The Tip of the Iceberg
date: 2020-05-19
journal: Am J Med
DOI: 10.1016/j.amjmed.2020.04.009
sha: 5d50b65148200788f2cce8310d02818f61be4a16
doc_id: 746395
cord_uid: cydf45t1

nan

. Further, the availability of several lifesaving, but prohibitively expensive to some, drugs (5) (6) (7) (8) or a vaccine (9) in the United States, have also led to marked increases in racial inequalities in mortality among Blacks compared to Whites.

As Santayana aptly noted in 1905, "Those who cannot remember the past are condemned to repeat it." (12) In these regards, there are clear short term clinical and public health challenges that include greater access to and utilization of healthcare by Blacks and all disadvantaged minorities within the United States.

With respect to COVID-19, now is the time to commit to short term as well as long term clinical and public health challenges. All should be considered in the context of the unique barriers that exist in Black and other disadvantaged minorities in underserved communities. Despite the markedly increased logistical challenges, these include the achievement of equalities in the widespread rapid testing for the virus and its antibody, combined with public health education on social distancing and handwashing, and access to medical care, to decrease the racial inequalities in morbidity and mortality of COVID-19. In addition, the clinical and public health challenges should include numerous sustainable and multiple preventive and therapeutic strategies that have already been identified to be contributing to racial 5 inequalities in mortality between Blacks and other disadvantaged minorities compared with Whites.

In this manuscript we offer what we believe to be the most important and timely long term clinical and public health challenges to combat racial inequalities in mortality from COVID-19. Specifically, it is our strong belief that the most major clinical and public health challenges will be long term. They will inevitably result from the development of an effective vaccine for COVID-19, which may or may not occur during the next 12 to 18 months. If an effective and safe vaccine becomes available this intervention will be lifesaving. As has been the case before, the introduction of this lifesaving innovation is likely to further increase racial inequalities that already adversely affect Blacks and other disadvantaged minorities.

For example, the advent of lifesaving highly active antiretroviral therapy for human immunodeficiency syndrome was accompanied by increases in racial inequalities. Specifically, Black: White mortality rate ratios among men increased from 3.2 to 6.6 (25-34 years), to 3.7 to 6.2 (35-44), 3.9 to 8.6 (45-54), 4.5 to 9.5 In addition, for respiratory distress syndrome, there was a nationwide reversal from a survival advantage to a survival disadvantage for Blacks following the introduction of surfactant. (7) Most recently, similar increases in racial inequalities in mortality from hepatocellular cancer occurred followed the licensure of lifesaving, but prohibitively expensive for some, drugs for hepatitis C virus which is a major risk factor. (8) Perhaps of greatest direct relevance to COVID-19 were the experiences before and after the development of the Salk vaccine for poliomyelitis (9) . In 1952, before the introduction of the vaccine, Blacks experienced significantly lower rates of paralytic polio than Whites. These observations were hypothesized to be related to herd immunity among Black children resulting from immunity acquired from infections which did not lead to paralysis in infancy and early childhood. Specifically, the incidence rates in Des Moines, Iowa and Kansas City, Missouri were 3-fold greater in Whites than among Blacks. By 1959, after the widespread dissemination of the Salk vaccine, the incidence rate in Blacks rose to 21-fold greater among Whites in Des Moines and 33 fold greater in Kansas City. (9) With respect to COVID-19, it may well be too late during the current pandemic to address the multiple factors, which already impose greater morbidity 7 and mortality burdens on Blacks and other socio-economically disadvantaged groups. It is certainly important to conduct the high-quality research necessary to understand the factors responsible for observed increases in racial inequalities, which have been temporally related to the introduction of several lifesaving innovations. It would also be of importance to identify communities which appear to have been more successful in achieving more equitable distributions of these lifesaving innovations among Blacks and other disadvantaged minorities. To do so, however, will require leadership from clinical and public health officials whose visions should build upon and extend beyond the provision of resources for treating those who are ill today, beyond the identification and testing of promising but unproven diagnostic and therapeutic options, and, perhaps most importantly, far beyond the development of an effective vaccine.

In general, with respect to factors influencing inequalities in mortality between Blacks and Whites it is necessary to consider the issue of mistrust. (8, 10, 11) Clinical and public health challenges should include the reality that, even at present, the United States Public Health Service, for all of its valor, may still be White men. (10, 11) The beacon at the end of the tunnel for COVID-119 may be an effective vaccine which may or may not be available within the next two years. Based on the existing totality of evidence, we believe that the foremost clinical and public health priorities should be to achieve equality for all preventive, diagnostic, and therapeutic modalities of proven benefitparticularly and most urgently, the successful translation of vaccine research into practice. In the past the United States has appeared to have been far more adept at developing innovations than assuring that those innovations provide equal benefit to all people. Now is the time to address this crucial clinical and public health challenge. Death is inevitable but premature death is not. If the valuable lessons from the past experiences in the United States with human immunodeficiency virus(6), respiratory distress syndrome (7), hepatocellular cancer (8), the Salk vaccine for poliomyelitis (9) and

Mapping the worldwide spread of the coronavirus

Statistical association and causation: Contributions of different types of evidence

Black-white inequalities in mortality and lifeexpectancy, 1933-1999: Implications for Healthy People

Blacks-White mortality from HIV before and after introduction of highly active antiretroviral therapy in 1996

The increasing racial disparity in 10 infant mortality: Respiratory distress syndrome and other causes

A descriptive study of racial inequalities in mortality from hepatocellular cancer before and after licensure of lifesaving drugs for hepatitis C virus in the United States EClinical Medicine

The changing pattern of poliomyelitis observed in two urban epidemics. Public Health Rep

Tuskegee and the health of Blacks men

Report of the Secretary's Task Force on Black and Minority Health

The Life of Reason: Reason in Common Sense

which has discretionary investment authority; does not own any common or preferred stock in any pharmaceutical or medical device company.